Skip to content

ArtVentive Medical Group, Inc.: 10-Q filed 2012-08-08

What ArtVentive Medical Group, Inc. reported in its quarterly report filed 2012-08-08 (fiscal Q2 2012): 16 published measures, 48 facts as tagged in accession 0001056520-12-000350.

This filing

Form
10-Q (quarterly report)
Filed
2012-08-08
Fiscal period
fiscal Q2 2012
Accession
0001056520-12-000350 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All ArtVentive Medical Group, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-06-3063,443USD
At 2011-12-31101,193USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-06-30-407,921USD
At 2011-12-31-273,257USD

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-01-01 to 2012-06-30-237,611USD182
2007-01-23 to 2012-06-30-3,573,590USD1986
2011-01-01 to 2011-06-30-1,282,699USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-01-01 to 2012-06-30200,000USD182
2007-01-23 to 2012-06-303,636,080USD1986
2011-01-01 to 2011-06-301,600,000USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2007-01-23 to 2012-06-30-1,880USD1986

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2012-04-01 to 2012-06-3049,252,658shares91
2012-01-01 to 2012-06-3049,190,690shares182
2011-04-01 to 2011-06-3047,686,919shares91
2011-01-01 to 2011-06-3047,440,563shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-06-30737USD
At 2011-12-31876USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2012-04-01 to 2012-06-30-168,223USD91
2012-01-01 to 2012-06-30-334,676USD182
2007-01-23 to 2012-06-30-4,226,616USD1986
2011-04-01 to 2011-06-30-837,817USD91
2011-01-01 to 2011-06-30-1,273,501USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-06-3061,658USD
At 2011-12-3199,269USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-06-30471,364USD
At 2011-12-31374,450USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2012-04-01 to 2012-06-30106,239USD91
2012-01-01 to 2012-06-30179,953USD182
2007-01-23 to 2012-06-301,285,946USD1986
2011-04-01 to 2011-06-30216,680USD91
2011-01-01 to 2011-06-30296,752USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-04-01 to 2012-06-3061,915USD91
2012-01-01 to 2012-06-30154,585USD182
2007-01-23 to 2012-06-302,893,977USD1986
2011-04-01 to 2011-06-30621,068USD91
2011-01-01 to 2011-06-30976,611USD181

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-06-303,765,203USD
At 2011-12-313,565,403USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2012-06-30-645USD
At 2011-12-31-506USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2012-04-01 to 2012-06-30-168,218USD91
2012-01-01 to 2012-06-30-334,664USD182
2007-01-23 to 2012-06-30-4,222,573USD1986
2011-04-01 to 2011-06-30-837,697USD91
2011-01-01 to 2011-06-30-1,273,254USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2012-01-01 to 2012-06-3096,872USD182
2007-01-23 to 2012-06-30471,301USD1986
2011-01-01 to 2011-06-30-19,597USD181

Inspect the source

Entity
ArtVentive Medical Group, Inc. / CIK 0001405249
Captured
SEC response SHA-256
01b8937f2876d513617b1d921d4a98ec6f536680d197470785bad286f4947f07

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001405249.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))